<DOC>
	<DOCNO>NCT00571506</DOCNO>
	<brief_summary>The purpose study examine effect two diabetes medication , rosiglitazone pioglitazone , marker vascular disease subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Thiazolidinedione Treatment Vascular Risk Markers</brief_title>
	<detailed_description>Diabetes common disease United States , affect 10 million Americans . Vascular disease , include heart attack stroke , affect many diabetic patient cause death three-fourths patient . Because majority diabetic patient suffer complication death vascular disease , explore treatment potential reduce prevent vascular disease type 2 diabetes patient . Our study examine effect two diabetes medication , rosiglitazone ( ROSI ) pioglitazone ( PIO ) , marker vascular disease 20 subject type 2 diabetes . It think two medication reduce risk vascular disease affect platelet proteins regulate process involve clot formation . One-half subject enrol study take ROSI half take PIO . We measure clump ability subject ' platelet , , three month treatment ROSI PIO . We measure blood concentration several protein ( fibrinogen , PAI-1 , CRP , adiponectin , leptin ) treatment study drug . These experiment give u information beneficial effect ROSI PIO clot-forming ability diabetes patient . We expect treatment ROSI PIO result improvement disturb clot-forming process predispose diabetic patient vascular disease .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<criteria>Men woman race Age 4065 year Diagnosis type 2 diabetes hemoglobin A1C â‰¥ 7 % eligible whether currently take antihyperglycemic medication History rosiglitazone pioglitazone use previous 3 month Known diagnosis peripheral vascular disease cardiac failure Recent history ( within past 6 month ) ischemic stroke , myocardial infarction , percutaneous coronary intervention , coronary artery bypass surgery Active liver disease elevate serum transaminase ( ALT &gt; 2.5x upper limit normal ) Current therapy oral anticoagulant ( warfarin , heparin , low molecular weight heparin ) , clopidogrel , immunosuppressive agent Pregnancy breastfeed Any condition , opinion investigator , render subject unable complete study , interfere optimal participation study , produce significant risk subject</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>Vascular Diseases</keyword>
	<keyword>Thiazolidinediones</keyword>
	<keyword>Platelet Aggregation</keyword>
</DOC>